470

Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470

Retrieved on: 
Monday, October 31, 2022

NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is currently in a Phase 3 clinical program.

Key Points: 
  • NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is currently in a Phase 3 clinical program.
  • These results demonstrate that NCX 470 has a robust intraocular pressure lowering effect, with good tolerability, and that it clearly met the primary objective of the Mont Blanc Phase 3 trial.
  • The difference in IOP reduction between NCX 470 and latanoprost was up to 1.0 mmHg in favor of NCX 470.
  • NCX 470 was well tolerated; the most common adverse event was ocular hyperemia in 11.9% of the NCX 470 patients vs. 3.3% of latanoprost patients.

Nicox Provides First Half 2022 Business Update and Financial Results

Retrieved on: 
Friday, September 16, 2022

Topline results from first pivotal Phase 3 glaucoma clinical trial on NCX 470, Mont Blanc, due in November 2022

Key Points: 
  • Topline results from first pivotal Phase 3 glaucoma clinical trial on NCX 470, Mont Blanc, due in November 2022
    Net revenue 1.4 million for H1 2022; cash of 31.6 million on June 30, 2022
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided business and financial results for Nicox SA and its subsidiaries (the Nicox Group) for the first half of 2022.
  • I am delighted to have joined Nicox at such an important time in the companys history.
  • Operating expenses for the first half of 2022 were 12.7 million compared to 13.4 million for the first half of 2021.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Nicox Provides Second Quarter 2022 Financial and Business Highlights

Retrieved on: 
Wednesday, July 20, 2022

Net revenue 0.7 million for second quarter 2022; cash of 31.6 million on June 30, 2022

Key Points: 
  • Net revenue 0.7 million for second quarter 2022; cash of 31.6 million on June 30, 2022
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided financial and business highlights for second quarter 2022 for Nicox SA and its subsidiaries (the Nicox Group) and updated on key upcoming milestones.
  • Net revenue1 for the second quarter of 2022 was 0.7 million (consisting entirely of net royalty payments).
  • Net revenue1 for the second quarter of 2021 was 0.7 million (including 0.6 million of net royalty payments).
  • Andreas Segerros joined Nicox as Chief Executive Officer on June 1, 2022.

Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022

Retrieved on: 
Friday, June 3, 2022

The Phase 2 efficacy results showed up to 1.4 mmHg superior intraocular pressure lowering with NCX 470 compared to latanoprost 0.005%.

Key Points: 
  • The Phase 2 efficacy results showed up to 1.4 mmHg superior intraocular pressure lowering with NCX 470 compared to latanoprost 0.005%.
  • The Mont Blanc trial is testing a higher concentration of NCX 470, and so could potentially demonstrate even greater efficacy.
  • Mont Blanc is a Phase 3 clinical trial in patients with elevated intraocular pressure due to open-angle glaucoma or ocular hypertension.
  • The Mont Blanc Phase 3 trial had an initial adaptive design period during which NCX 470 0.065% was evaluated together with the higher concentration of NCX 470 0.1%.

Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma

Retrieved on: 
Monday, April 11, 2022

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the results from its Dolomites Phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma, the official journal of the World Glaucoma Association.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the results from its Dolomites Phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma, the official journal of the World Glaucoma Association.
  • Dolomites was a dose-response Phase 2 clinical trial comparing three concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) to latanoprost ophthalmic solution, 0.005% in 433 patients with open-angle glaucoma or ocular hypertension.
  • All tested concentrations of NCX 470 were statistically non-inferior to latanoprost and the dose response of NCX 470 showed improved IOP lowering with each incremental concentration.
  • NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali.

Nicox Provides Fourth Quarter 2021 Business and Financial Highlights

Retrieved on: 
Friday, January 21, 2022

VYZULTA and ZERVIATEfourth quarter U.S. prescriptions increased by 39% and 129%, respectively, in 2021 vs. 2020

Key Points: 
  • VYZULTA and ZERVIATEfourth quarter U.S. prescriptions increased by 39% and 129%, respectively, in 2021 vs. 2020
    Net revenue of 3.5 million in the fourth quarter of 2021, 7.2 million for 2021; cash of 41.9 million on December 31, 2021
    Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, provided business and financial highlights for fourth quarter 2021 for Nicox SA and its subsidiaries (the Nicox Group) as well as key expected value-inflection milestones today.
  • As of December 31, 2021, the Nicox Group had cash and cash equivalents of 41.9 million as compared with 32.7 million at September 30, 2021 and 47.2 million at December 31, 2020.
  • Net revenue1 for the fourth quarter of 2020 was 5.8 million (0.3 million royalty payments, 5.5 million license payments).
  • Fourth quarter revenue for VYZULTA in 2021 was impacted by additional rebates due to year-end true-up calculations.

Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model

Retrieved on: 
Wednesday, September 29, 2021

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1).

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1).
  • The exploratory nonclinical studies reported today investigated the potential protective effects of NCX 470 on the retina and the optic nerve head.
  • Nonclinical experiments were performed to determine the effect of NCX 470 on ocular vascular reactivity and retinal function after repeated topical ocular dosing in a well-defined model of ischemia/reperfusion injury to the optic nerve in rabbits induced by ET-1.
  • Nicoxs lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma.

Nicox First Half 2021 Financial Results and Business Update

Retrieved on: 
Monday, September 27, 2021

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported the financial results for Nicox SA and its subsidiaries (the Nicox Group) for the six months ending June 30, 2021 and provided an update on recent events as well as progress on key programs.

Key Points: 
  • Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today reported the financial results for Nicox SA and its subsidiaries (the Nicox Group) for the six months ending June 30, 2021 and provided an update on recent events as well as progress on key programs.
  • Net revenue1 for the first half of 2021 was 1.3 million (including 1.2 million in royalty revenue) versus 2.4 million (including 1.4 million in royalty revenue) for the first half of 2020.
  • Operating expenses for the first half of 2021 were 13.3 million compared to 10.2 million for the first half of 2020.
  • As of June 30, 2021, the Nicox Group had cash and cash equivalents of 36.5 million, as compared with 42.0 million at March 31, 2021 and 47.2 million at December 31, 2020.